CV8102


Associated tags: Degenerative disease, Neck, RECIST, B cell, Squamous cell carcinoma, Head, COVID-19, RNA transfection, Neoplasm, Tumor microenvironment, ESMO, Safety, Immune system, Infection, Vaccine, Patient, Adenoid cystic carcinoma, Oncology, Cell, PD-1

EQS-News: CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

Retrieved on: 
Friday, November 11, 2022
Degenerative disease, Adenoid cystic carcinoma, Melanoma, SITC, Society, CVAC, CureVac, Protein, RNA, European Society for Medical Oncology, Immunotherapy, GSK, Biopsy, Technology, PD-1, Cell, Oncology, Patient, Neck, Vaccine, Infection, Immune system, Safety, ESMO, Tumor microenvironment, Neoplasm, RNA transfection, COVID-19, Head, Nasdaq, Squamous cell carcinoma, B cell, RECIST, Pharmaceutical industry

TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.

Key Points: 
  • TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.
  • Preliminary results from the completed Phase 1 expansion study in patients with PD-1 refractory melanoma confirm a robust safety profile of CV8102 as a single agent and in combination with anti-PD-1 antibodies.
  • The data we collected in the heavily pretreated patients of our Phase 1 expansion study further confirm the safety and immuno-modulatory activity of CV8102, said Ulrike Gnad-Vogt, interim Chief Development Officer at CureVac.
  • The Phase 1, open-label, dose escalation and expansion study of CV8102 aims to assess safety, tolerability and efficacy of CV8102 as a single agent and in combination with licensed PD1-antibodies.

DGAP-News: CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma

Retrieved on: 
Thursday, February 4, 2021
Cancer treatments, Medicine, Clinical medicine, Orphan drugs, Cancer, Melanoma, Breakthrough therapy, Antineoplastic drugs, Pexastimogene devacirepvec, PD-1 and PD-L1 inhibitors

Initial results from the dose-escalation part in four solid cancer types were presented at the SITC conference in 2020.

Key Points: 
  • Initial results from the dose-escalation part in four solid cancer types were presented at the SITC conference in 2020.
  • CV8102 had shown promising evidence of efficacy after intratumoral application as a single agent, and in combination with systemic anti-PD-1 antibody treatment.
  • The objective of the expansion is to confirm safety, tolerability, and efficacy of CV8102 in patients with advanced melanoma at 600g, the selected dose to be advanced in a Phase 2 clinical trial.
  • "The CV8102 trial expansion is expected to provide further insights into clinical efficacy and mechanism of action in patients with advanced PD-1 refractory melanoma, an indication with a high unmet medical need.